ROCHE
ActiveFrom the official registers: KBO 57 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
ROCHE has been active since 1924 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €64.5m and a net result of €8.7m. Equity has been growing by about 6.4% per year since 2018. Its solvency ranks better than 41% of 94 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Official details
KBO- Status
- Active since 12-02-1924 Normal situation
- Legal form
- Public limited company
- Registered office
- Dantestraat 75, 1070 Anderlecht
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21201and 2 others
- Establishment units
- 2.003.056.631 1070 Anderlecht, since 01-02-1924
- 2.378.693.287 1831 Machelen (Brab.), since 27-10-2025
- Financial year end
- 31 December
- Peppol
- Reachable since 25-09-2025
Board and ownership
Board
- Silvia BARCELEIROManaging director
- Lisandro ZarateDirector
- Isabel JOERINDirector
- Youssef EHAB ABDELMONEIMDirector
- Auditor
- KPMG Bedrijfsrevisoren BV/SRL
Shareholders
- Roche Holding SAconsolidatesannual accounts 2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.3%
Annual accounts 2025
- Turnover
- €448.8m
- ▼ 0.5%
- Profit
- €8.7m
- ▲ 10.9%
- Equity
- €64.5m
- ▲ 15.7%
- Total assets
- €164.7m
- ▼ 13.5%
- Staff
- 122.7 FTE
- ▼ 7.5%
2025 accounts filed 52 days before the deadline
Filed on 09-06-2026PDF
Score breakdownraises riskLiquidity: current ratio 1.621 of the last 3 accounts latelowers riskFounded in 1924Size: turnover €448.8m, 122.7 FTE, total assets €164.7mShow the evidence
Checked score
Score 2025
85
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 38% of companies in pharmaceuticals (NACE 21)
Financial strength · tick: 2024
Average
Solvency
64+10
equity 39.1% of total assets
Liquidity
38+24
short-term debt 59.3%
Profitability
61+2
return on assets 5.3%
Bankruptcy probability within 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.1%
12-2024: 0.1%● unchanged vs 11-2024
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025lowest value
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.3%▲ +0.2 percentage points vs 06-2025
08-2025: 0.3%● unchanged vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.3%● unchanged vs 05-2026highest value
07-2026: 0.3%● unchanged vs 06-2026
08-2026: 0.3%● unchanged vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026
Credit of up to €5,450,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.62 (1.4 in 2024), above the usual 1.5. Short-term debt is 59.3% of total assets. However, 60.9% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21). It does better than 34% of them on solvency, 41% on liquidity, 29% on profitability and 48% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-06-2026, 52 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
52 days early
2024
44 days early
2023
188 days late
2022
83 days early
2021
93 days early
2020
94 days early
2019
85 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 38 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 9 June (4 of the last 5 filed years within 41 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials · financial year 2025, full format
In the rankings
#1 oldest company in Belgium, Pharmaceuticals sector#3 company by total assets in the Brussels-Capital Region, Pharmaceuticals sector#3 company by equity in the Brussels-Capital Region, Pharmaceuticals sector
Latest annual accounts filed
Annual accounts 2025
- Financial year ended
- 31-12-2025
- Filed on
- 09-06-2026
- Format
- full format
- Reference
- 2026-00148910
Turnover
€448.8m▼ 0.5%
2024 · €451.2m
EBIT margin
2.8%▲ 0.3pp
2024 · 2.5%
Net result
€8.7m▲ 10.9%
2024 · €7.9m
Working capital
€60.6m▲ 16.4%
2024 · €52.0m
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result for 2025 is 11% higher than in 2024 and the highest since 2021. It is the third rise in a row, after the fall in 2022.
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Turnover€448.8m
2025
Operating result€12.4m
2025
Net result€8.7m
2025
Assets, equity and debt per financial year.
Total assets€164.7m
2025
Equity€64.5m
2025
Debt€97.7m
2025
Above zero, the company can pay its short-term debts with what it holds in the short term.
Working capital€60.6m
2025
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
EBIT margin2.8%
2025
Return on assets (ROA)5.3%
2025
The higher the solvency, the better the company absorbs a setback.
Solvency39.1%
2025
A ratio above 1 means the short-term assets cover the short-term debts.
Current ratio1.62
2025
Average staff per financial year, in full-time equivalents (FTE).
Staff (FTE)122.7
2025
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio, return on assets (ROA) and staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Turnover€271.0m-€304.2m▲ 12.3%€389.0m▲ 27.9%€403.9m▲ 3.8%€403.3m▼ 0.1%€421.0m▲ 4.4%€451.2m▲ 7.2%€448.8m▼ 0.5%
Operating result€4.1m-€4.2m▲ 4.5%€5.0m▲ 18.3%€11.6m▲ 130%€10.1m▼ 12.4%€10.6m▲ 4.3%€11.2m▲ 6.0%€12.4m▲ 11.1%
Net result€2.3m-€2.2m▼ 6.1%€3.9mabove the sector's middle half▲ 81.5%€8.5mabove the sector's middle half▲ 117%€8.6mabove the sector's middle half▲ 1.2%€8.9mabove the sector's middle half▲ 3.0%€7.9mabove the sector's middle half▼ 11.1%€8.7mabove the sector's middle half▲ 10.9%
EBIT margin1.5%-1.4%▼ 0.1pp1.3%▼ 0.1pp2.9%▲ 1.6pp2.5%▼ 0.4pp2.5%=2.5%=2.8%▲ 0.3pp
Equity€41.8m-€43.9m▲ 5.2%€43.9mabove the sector's middle half▼ 0.2%€52.4mabove the sector's middle half▲ 19.4%€61.0mabove the sector's middle half▲ 16.4%€69.8mabove the sector's middle half▲ 14.5%€55.7mabove the sector's middle half▼ 20.2%€64.5mabove the sector's middle half▲ 15.7%
Total assets€101.9m-€124.9m▲ 22.5%€172.1mabove the sector's middle half▲ 37.8%€140.1mabove the sector's middle half▼ 18.6%€160.4mabove the sector's middle half▲ 14.5%€189.3mabove the sector's middle half▲ 18.0%€190.4mabove the sector's middle half▲ 0.6%€164.7mabove the sector's middle half▼ 13.5%
Debt€45.0m-€62.7m▲ 39.3%€112.3m▲ 79.1%€73.9m▼ 34.2%€92.6m▲ 25.3%€114.7m▲ 23.9%€130.1m▲ 13.4%€97.7m▼ 24.9%
Working capital€45.2m-€51.1m▲ 13.1%€49.4mabove the sector's middle half▼ 3.4%€56.3mabove the sector's middle half▲ 14.0%€58.3mabove the sector's middle half▲ 3.5%€65.6mabove the sector's middle half▲ 12.6%€52.0mabove the sector's middle half▼ 20.7%€60.6mabove the sector's middle half▲ 16.4%
Solvency41.0%-35.2%▼ 5.8pp25.5%within the sector's middle half▼ 9.7pp37.4%within the sector's middle half▲ 11.9pp38.0%within the sector's middle half▲ 0.6pp36.9%within the sector's middle half▼ 1.1pp29.3%within the sector's middle half▼ 7.6pp39.1%within the sector's middle half▲ 9.9pp
Current ratio2.00-1.82▼ 0.191.44within the sector's middle half▼ 0.381.76within the sector's middle half▲ 0.321.63within the sector's middle half▼ 0.131.57within the sector's middle half▼ 0.061.40within the sector's middle half▼ 0.171.62within the sector's middle half▲ 0.22
Return on assets (ROA)2.3%-1.7%▼ 0.5pp2.3%within the sector's middle half▲ 0.5pp6.1%within the sector's middle half▲ 3.8pp5.4%within the sector's middle half▼ 0.7pp4.7%within the sector's middle half▼ 0.7pp4.1%within the sector's middle half▼ 0.5pp5.3%within the sector's middle half▲ 1.2pp
Staff (FTE)160.9-159▼ 1.2%154.3above the sector's middle half▼ 3.0%152.7above the sector's middle half▼ 1.0%146.4above the sector's middle half▼ 4.1%144.6above the sector's middle half▼ 1.2%132.6within the sector's middle half▼ 8.3%122.7above the sector's middle half▼ 7.5%
above
within
below
The sector band is the middle half of the companies in Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €164.7m
Fixed assets
€6.4m ▼ 22.5%
Current assets
€158.3m ▼ 13.1%
Equity and liabilities €164.7m
Equity
€64.5m ▲ 15.7%
Provisions
€2.5m ▼ 45.1%
Debt
€97.7m ▼ 24.9%
Debt's share of the balance-sheet total falls from 68.3% to 59.3%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€13.2m▲
2024 · €12.0m
Cash flow
€9.5m▲
2024 · €8.6m
Quick ratio
1.05▲
2024 · 0.86
Debt to equity
1.52▼
2024 · 2.34
ROE
13.6%▼
2024 · 14.2%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€97.7m▼
2024 · €130.1m
Income taxes
€2.8m▼
2024 · €3.4m
Staff costs
€28.1m▼
2024 · €28.5m
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Companies with the same profile, two years later
Historical observationIn July 2024, 1,579 companies had the same profile as ROCHE has now. Two years later, 0.1% had gone bankrupt and 96.7% were still going.
- Medium-sized
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.1%
went bankrupt
3.2%
stopped otherwise
96.7%
was still going
That fits the bankruptcy probability of ROCHE itself: 0.3% within 12 months.
Test of the method
The method was tested on the 497,445 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,579 companies, not a prediction for ROCHE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | €333.2m | €410.9m | €428.8m | €427.6m | €442.7m | €472.5m | €471.9m | ▼ 0.1% |
| Turnover70 | €271.0m | €304.2m | €389.0m | €403.9m | €403.3m | €421.0m | €451.2m | €448.8m | ▼ 0.5% |
| Other operating income74 | - | €23.0m | €21.9m | €24.9m | €24.3m | €21.7m | €21.3m | €23.0m | ▲ 8.1% |
| Non-recurring operating income76A | - | €5.9m | - | - | - | - | - | €0.02m | - |
| Operating charges60/66A | - | €328.9m | €405.9m | €417.2m | €417.5m | €432.2m | €461.3m | €459.4m | ▼ 0.4% |
| Goods for resale, raw materials and consumables60 | - | €199.1m | €237.2m | €225.4m | €252.1m | €261.9m | €260.8m | €259.9m | ▼ 0.3% |
| Purchases600/8 | - | - | - | - | - | €267.2m | €282.8m | €247.2m | ▼ 12.6% |
| Change in stocks: decrease (increase)609 | - | €1.4m | -€19.6m | €24.7m | -€2.1m | -€5.3m | -€22.1m | €12.8m | - |
| Services and other goods61 | - | €23.3m | €23.5m | €23.6m | €22.1m | €19.6m | €19.7m | €21.1m | ▲ 7.0% |
| Remuneration, social security and pensions62 | - | €25.8m | €26.4m | €30.6m | €27.3m | €27.7m | €28.5m | €28.1m | ▼ 1.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.7m | ▼ 3.2% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | €0.1m | €0.8m | €1.9m | -€0.4m | -€2.3m | €0.6m | €1.2m | ▲ 117% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | €3.1m | -€2.3m | -€2.1m | -€7.0m | -€2.1m | -€0.1m | -€2.1m | ▼ 1,592% |
| Other operating charges640/8 | - | €76.7m | €119.4m | €137.0m | €122.6m | €126.5m | €151.1m | €148.6m | ▼ 1.7% |
| Non-recurring operating charges66A | - | - | - | - | - | - | - | €1.8m | - |
| Operating profit (loss)9901 | €4.1m | €4.2m | €5.0m | €11.6m | €10.1m | €10.6m | €11.2m | €12.4m | ▲ 11.1% |
| Financial income75/76B | - | - | - | - | - | €1.6m | €1.4m | €0.5m | ▼ 67.6% |
| Recurring financial income75 | €0.03m | €0.06m | €0.02m | €0.002m | €0.3m | €1.6m | €1.4m | €0.5m | ▼ 67.6% |
| Income from current assets751 | - | - | - | - | €0.3m | €1.6m | €1.4m | €0.5m | ▼ 67.6% |
| Other financial income752/9 | - | €0.06m | €0.02m | €0.002m | €0.001m | €0.001m | €0.001m | €0.001m | ▲ 1.4% |
| Financial charges65/66B | - | €0.02m | €0.01m | €0.3m | €0.3m | €0.3m | €1.4m | €1.3m | ▼ 3.8% |
| Recurring financial charges65 | €0.03m | €0.02m | €0.01m | €0.3m | €0.3m | €0.3m | €1.4m | €1.3m | ▼ 3.8% |
| Debt charges650 | - | - | - | - | - | - | €0.06m | €0.06m | ▼ 7.2% |
| Other financial charges652/9 | - | €0.02m | €0.01m | €0.3m | €0.3m | €0.3m | €1.3m | €1.3m | ▼ 3.6% |
| Profit (loss) for the period before taxes9903 | €4.1m | €4.3m | €5.0m | €11.2m | €10.1m | €11.9m | €11.3m | €11.6m | ▲ 3.0% |
| Income taxes67/77 | €1.8m | €2.1m | €1.1m | €2.7m | €1.5m | €3.0m | €3.4m | €2.8m | ▼ 15.4% |
| Taxes670/3 | - | €2.2m | €1.2m | €2.7m | €1.5m | €3.3m | €3.4m | €2.8m | ▼ 15.4% |
| Tax adjustments and reversals of tax provisions77 | - | €0.06m | €0.05m | - | - | €0.3m | €0 | - | - |
| Profit (loss) for the period9904 | €2.3m | €2.2m | €3.9m | €8.5m | €8.6m | €8.9m | €7.9m | €8.7m | ▲ 10.9% |
| Transfer from tax-exempt reserves789 | - | - | - | - | - | - | €1.3m | - | - |
| Profit (loss) for the period to be appropriated9905 | €2.3m | €2.2m | €3.9m | €8.5m | €8.6m | €8.9m | €9.2m | €8.7m | ▼ 4.9% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €101.9m | €124.9m | €172.1m | €140.1m | €160.4m | €189.3m | €190.4m | €164.7m | ▼ 13.5% |
| Fixed assets21/28 | €11.7m | €11.0m | €10.5m | €9.9m | €9.5m | €8.9m | €8.3m | €6.4m | ▼ 22.5% |
| Tangible fixed assets22/27 | €11.7m | €11.0m | €10.4m | €9.9m | €9.5m | €8.9m | €8.3m | €6.4m | ▼ 22.5% |
| Land and buildings22 | - | €10.8m | €10.3m | €9.6m | €9.3m | €8.8m | €8.2m | €5.7m | ▼ 30.4% |
| Plant, machinery and equipment23 | - | €0.05m | €0.03m | €0.1m | €0.1m | €0.04m | €0.03m | €0.05m | ▲ 95.6% |
| Furniture and vehicles24 | - | €0.1m | €0.1m | €0.2m | €0.1m | €0.1m | €0.1m | €0.05m | ▼ 43.4% |
| Assets under construction and advance payments27 | - | - | - | - | - | - | - | €0.6m | - |
| Financial fixed assets28 | €0.01m | €0.02m | €0.02m | €0.03m | €0.01m | - | - | - | - |
| Other financial fixed assets284/8 | - | €0.02m | €0.02m | €0.03m | €0.01m | - | - | - | - |
| Amounts receivable and cash guarantees285/8 | - | €0.02m | €0.02m | €0.03m | €0.01m | - | - | - | - |
| Current assets29/58 | €90.2m | €113.8m | €161.6m | €130.2m | €150.9m | €180.4m | €182.1m | €158.3m | ▼ 13.1% |
| Stocks and contracts in progress3 | €47.5m | €46.0m | €64.8m | €38.1m | €40.6m | €48.2m | €69.7m | €55.9m | ▼ 19.8% |
| Stocks30/36 | - | €46.0m | €64.8m | €38.1m | €40.6m | €48.2m | €69.7m | €55.9m | ▼ 19.8% |
| Goods purchased for resale34 | - | €46.0m | €64.8m | €38.1m | €40.6m | €48.2m | €69.7m | €55.9m | ▼ 19.8% |
| Amounts receivable within one year40/41 | €38.4m | €45.3m | €54.7m | €48.0m | €60.1m | €85.5m | €112.4m | €102.3m | ▼ 9.0% |
| Trade receivables40 | - | €44.3m | €54.3m | €47.8m | €60.1m | €55.1m | €71.0m | €65.8m | ▼ 7.3% |
| Other amounts receivable41 | - | €1.0m | €0.4m | €0.2m | - | €30.4m | €41.4m | €36.5m | ▼ 11.9% |
| Cash at bank and in hand54/58 | €4.1m | €22.5m | €42.1m | €44.1m | €50.1m | €46.6m | €0 | - | - |
| Deferred charges and accrued income490/1 | - | €0.04m | €0.06m | €0.02m | €0.006m | €0.007m | €0.03m | €0.08m | ▲ 145% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €101.9m | €124.9m | €172.1m | €140.1m | €160.4m | €189.3m | €190.4m | €164.7m | ▼ 13.5% |
| Equity10/15 | €41.8m | €43.9m | €43.9m | €52.4m | €61.0m | €69.8m | €55.7m | €64.5m | ▲ 15.7% |
| Contributions10/11 | €32.0m | €32.0m | €33.2m | €33.2m | €33.2m | €33.2m | €33.2m | €33.2m | = |
| Capital10 | - | €32.0m | €32.0m | €32.0m | €32.0m | €32.0m | €32.0m | €32.0m | = |
| Issued capital100 | - | €32.0m | €32.0m | €32.0m | €32.0m | €32.0m | €32.0m | €32.0m | = |
| Contributions outside capital11 | - | €1.2m | €1.2m | €1.2m | €1.2m | €1.2m | €1.2m | €1.2m | = |
| Share premium1100/10 | - | - | - | €1.2m | €1.2m | €1.2m | €1.2m | €1.2m | = |
| Reserves13 | €3.8m | €5.3m | €5.3m | €5.3m | €5.3m | €5.3m | €5.3m | €5.3m | = |
| Non-distributable reserves130/1 | - | - | €3.2m | €3.2m | €3.2m | €3.2m | €3.2m | €3.2m | = |
| Legal reserve130 | - | €3.2m | €3.2m | €3.2m | €3.2m | €3.2m | €3.2m | €3.2m | = |
| Tax-exempt reserves132 | - | €1.3m | €1.3m | €1.3m | €1.3m | €1.3m | €0 | - | - |
| Distributable reserves133 | - | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €2.1m | €2.1m | = |
| Profit (loss) carried forward14 | €4.7m | €5.4m | €5.3m | €13.8m | €22.4m | €31.3m | €17.2m | €25.9m | ▲ 50.8% |
| Provisions and deferred taxes16 | €15.1m | €18.2m | €16.0m | €13.9m | €6.9m | €4.7m | €4.6m | €2.5m | ▼ 45.1% |
| Provisions for liabilities and charges160/5 | - | €18.2m | €16.0m | €13.9m | €6.9m | €4.7m | €4.6m | €2.5m | ▼ 45.1% |
| Pensions and similar obligations160 | - | €17.7m | €15.4m | €13.8m | €6.8m | €4.6m | €4.5m | €2.4m | ▼ 47.4% |
| Other liabilities and charges164/5 | - | €0.6m | €0.6m | €0.1m | €0.1m | €0.1m | €0.1m | €0.2m | ▲ 47.6% |
| Amounts payable17/49 | €45.0m | €62.7m | €112.3m | €73.9m | €92.6m | €114.7m | €130.1m | €97.7m | ▼ 24.9% |
| Amounts payable within one year42/48 | €45.0m | €62.7m | €112.3m | €73.9m | €92.6m | €114.7m | €130.1m | €97.7m | ▼ 24.9% |
| Financial debts43 | - | - | - | - | - | - | €14.2m | €11.4m | ▼ 19.6% |
| Other loans439 | - | - | - | - | - | - | €14.2m | €11.4m | ▼ 19.6% |
| Trade debts44 | €24.1m | €47.2m | €86.3m | €55.0m | €85.4m | €106.5m | €84.7m | €77.8m | ▼ 8.2% |
| Suppliers440/4 | - | €47.2m | €86.3m | €55.0m | €85.4m | €106.5m | €84.7m | €77.8m | ▼ 8.2% |
| Taxes, remuneration and social security45 | - | €15.5m | €22.0m | €18.8m | €7.2m | €8.2m | €9.2m | €8.5m | ▼ 7.4% |
| Taxes450/3 | - | €7.4m | €16.1m | €11.1m | €0.06m | €1.0m | €1.2m | €0.7m | ▼ 40.1% |
| Remuneration and social security454/9 | - | €8.2m | €5.9m | €7.8m | €7.2m | €7.2m | €8.1m | €7.8m | ▼ 2.7% |
| Other amounts payable47/48 | - | - | €4.0m | - | - | - | €22.0m | €0.007m | ▼ 100.0% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €2.3m | €2.2m | €3.9m | €8.5m | €8.6m | €8.9m | €7.9m | €8.7m | ▲ 10.9% |
| + Depreciation and write-downs630 | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.7m | ▼ 3.2% |
| Operating cash flow (approximation) | €3.1m | €3.0m | €4.7m | €9.3m | €9.4m | €9.7m | €8.6m | €9.5m | ▲ 9.6% |
| Investment in fixed assets (approximation) | - | -€0.1m | -€0.2m | -€0.2m | -€0.4m | -€0.2m | -€0.1m | €1.1m | - |
| Change in cash | - | €18.3m | €19.6m | €2.0m | €6.1m | -€3.6m | -€46.6m | - | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 57 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | full format | 09-06-2026 | 2026-00148910 | |
| 31-12-2024 | full format | 17-06-2025 | 2025-00143701 | |
| 31-12-2023 | full format | 04-02-2025 | 2025-00025641 | |
| 31-12-2022 | full format | 09-05-2023 | 2023-00085083 | |
| 31-12-2021 | full format | 29-04-2022 | 2022-20016425 | |
| 31-12-2020 | full format | 28-04-2021 | 2021-11600579 | |
| 31-12-2019 | full format | 07-05-2020 | 2020-11800451 | |
| 31-12-2018 | full format | 29-04-2019 | 2019-10900446 | |
| 31-12-2017 | full format | 03-05-2018 | 2018-12200529 | |
| 31-12-2016 | full format | 28-04-2017 | 2017-10900117 |
Comparable companies
These companies have the same main activity as ROCHE: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €153m and €377m, founded between 1954 and 1999.
| Company | Founded | Total assets | Equity | Turnover | Net result | FTE | Financial year |
|---|---|---|---|---|---|---|---|
| ROCHE Anderlecht | 1924 | €164.7m | €64.5m | €448.8m | €8.7m | 122.7 | 2025 |
| Pfizer Elsene | 1954 | €377.4m | - | €358.3m | €3.7m | 297 | 2025 |
| LABORATOIRES S.M.B. Sint-Jans-Molenbeek | 1978 | €261.5m | €172.9m | €112.5m | €20.0m | 40 | 2025 |
| PHOENIX Pharma Belgium Sint-Lambrechts-Woluwe | 1983 | €235.4m | €46.5m | €1,325.4m | €3.8m | 496.7 | 2026 |
| Novartis Manufacturing Puurs-Sint-Amands | 1962 | €285.2m | €148.4m | €256.5m | €6.8m | 980 | 2025 |
| Organon Heist Heist-op-den-Berg | 1972 | €349.6m | €235.2m | €287.4m | €18.2m | 1,004.9 | 2025 |
| Novo Nordisk Production Belgium SA Brussel | 1999 | €153.5m | €74.2m | €258.6m | €11.9m | 587.2 | 2025 |
They were chosen from the 116 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Subsidies and aid
Flemish government
2022 to 2023 · 2 entries · €18,576 awarded · €18,576 paid| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2023 | 1 | €6,992 | €6,992 |
| 2022 | 1 | €11,584 | €11,584 |
Public contracts
16 awards · 2023 to 2026
Raamovereenkomst voor de aankoop en levering van bloedvormende middelen bij anemie: Heel langwerkend erythropoëtine
Parenterale cytostatica: Obinutuzumab
Raamovereenkomst voor het leveren van rituximab en trastuzumab: Rituximab subcutaan
Raamovereenkomst voor het leveren van rituximab en trastuzumab: Trastuzumab subcutaan
Centrale d'achat FHL: fourniture d’anticorps monoclonaux.: Atezolizumab
Show 11 more contracts
Raamovereenkomst voor het aankopen en leveren van Trastuzumab en Rituximab: Trastuzumab + Rituximab SC
Accord-cadre relatif à la fourniture de RITUXIMAB et de TRASTUZUMAB pour les besoins des pharmacies de Vivalia, agissant en Centrale d’achats: RITUXIMAB
Accord-cadre relatif à la fourniture de RITUXIMAB et de TRASTUZUMAB pour les besoins des pharmacies de Vivalia, agissant en Centrale d’achats: TRASTUZUMAB
Monoklonale antilichamen - Trastuzumab 2024: TRASTUZUMAB SC
Monoklonale antilichamen - Rituximab 2024: RITUXIMAB SC
Raamovereenkomst voor het leveren van Cytostatica Parenteraal: Atezolizumab infusie 840 mg / 14 ml
Raamovereenkomst voor het leveren van Cytostatica Parenteraal: Atezolizumab infusie 1.200 mg / 20 ml
Raamovereenkomst voor het leveren van Cytostatica Parenteraal: Rituximab injectie 1 400 mg / 11,7 ml
Raamovereenkomst voor het leveren van Cytostatica Parenteraal: Rituximab injectie 1 600 mg / 13,4 ml
Raamovereenkomst voor het leveren van Cytostatica Parenteraal: Trastuzumab emtansine infusie
Raamovereenkomst voor het leveren van Cytostatica Parenteraal: Trastuzumab injectie
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. The values are as the buyer published them. For a framework agreement, the value is a ceiling.
Directors
Directors
3 directors, 1 in day-to-day management, last change in 2026
Board 3
Lisandro Zarate
Current
Director · appointed in the act of 22-10-2026
Isabel JOERIN
Current
Director · in office according to the act of 28-11-2025
Youssef EHAB ABDELMONEIM
Current
Director · in office according to the act of 28-11-2025
Day-to-day management 1
Silvia BARCELEIRO
Current
Managing director · appointed in the act of 27-08-2026
Statutory auditor 1
KPMG Bedrijfsrevisoren BV/SRL
Current
Statutory auditor · since 14-10-2025 · permanent representative: Ellemarie Bex · listed in the 2025 annual accounts, filed on 09-06-2026
Mandate history
7 people, 5 in office
- Board
- Day-to-day management
- Statutory auditor
- began earlier
- end not dated
| Name | Functions and periods |
|---|---|
| Isabel JOERIN |
|
| Youssef EHAB ABDELMONEIM |
|
| Lisandro Zarate |
|
| Silvia BARCELEIRO |
|
| KPMG Bedrijfsrevisoren BV/SRL |
|
| Isabelle DECKER |
|
| Maria Johanna Borst |
|
The board according to the articles of association
Board and representation
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Het bestuursorgaan, evenals de gevolmachtigden voor het dagelijks bestuur binnen het kader van dit bestuur, mogen eveneens specifieke…”
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Raad kan voorzitter benoemen onder leden;bij ontstentenis of afwezigheid waarneemt oudste aanwezige bestuurder, raad van bestuur”
Audit, dissolution and liquidation
- Dissolution ruleThe articles set when and by whom the company can be dissolved.
- “Beraadslagt op wijze door wet vereist, algemene vergadering”
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Desgevallend één of meer vereffenaars benoemd door algemene vergadering, aandeelhouders verdelen liquidatiesaldo met inachtname…”
Articles of association, deed of 19-01-2024
Owners and capital
Shareholders
1 ownerChain of control
- Roche Holding SACH
- ROCHE
Owners 1
- Roche Holding SACHconsolidating parentconsolidates
Capital transactions
Capital over time
- 19-01-2024 Capital stated in the deed · €32,000,000 · 610,000 shares
Shares according to the articles of association
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- “Op naam, volgnummer”deed of 19-01-2024 (in French)
- Other provisionsThese rules from the articles cover subjects other than the board, the shares, the purpose and the meetings.
- 1 more provision in the deed, see the deed of 18-07-2024
Group and network
Connections & network
3 current directorsThe board mandates are in the list below. The network lets you explore the same ties.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Board mandates elsewhere
1 board mandateBoard mandates of ROCHEROCHE sits on their board1
History
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
22-10
Gazette deed
Resignation: Isabelle Decker (director)Appointment: Lisandro Zarate (director) · Power of attorney7 points ▸
Gazette deed
Resignation: Isabelle Decker (director)
Appointment: Lisandro Zarate (director) · Power of attorney7 points ▸
- General meeting, 15-09-2026
- Director resignation, Isabelle Decker (director)
- Director appointment, Lisandro Zarate (director)
- Power of attorney, Joris Beke Smets
- Power of attorney, Laura Vanden Bilcke
- Power of attorney
- Power of attorney, Ad-ministerie BV
27-08
Gazette deed
Resignation: Maria Johanna BORST (bestuurder)Appointment: Silvia BARCELEIRO (managing director) · Reappointments: I. JOERIN (director) and E. YOUSSEF (director) · Declaration27 points ▸
Gazette deed
Resignation: Maria Johanna BORST (bestuurder)
Appointment: Silvia BARCELEIRO (managing director) · Reappointments: I. JOERIN (director) and E. YOUSSEF (director) · Declaration27 points ▸
- Board meeting, 21-05-2026
- Declaration, “delegatie van bevoegdheden door de raad van bestuur aan welbepaalde personen zoals voor datum van deze vergadering gepubliceerd in het Belgisch Staatsblad niet…” (deed in Dutch)
- Power of attorney, Fabrizio LONGHI, mentioned 2 times in the deed
- Power of attorney, Nizar SEBTI, mentioned 2 times in the deed
- Power of attorney, Luc VAN DRIESSCHE, mentioned 2 times in the deed
- Power of attorney, Thomas LIMBEROPOULOS, mentioned 2 times in the deed
- Power of attorney, Geert BUTSTRAEN, mentioned 2 times in the deed
- Power of attorney, Stefaan FIERS, mentioned 2 times in the deed
- Power of attorney, Julie PIESSEVAUX, mentioned 2 times in the deed
- Power of attorney, Eva DE JONGH, mentioned 2 times in the deed
- Power of attorney, Maria Johanna BORST, mentioned 2 times in the deed
- Power of attorney, Silvia BARCELEIRO, mentioned 2 times in the deed
- The act holds 15 more points.
09-06
financial year 2025 · full format
2025
28-11
Gazette deed
Reappointments: Maria Johanna BORST, Isabel JOERIN and 3 othersPower of attorney24 points ▸
Gazette deed
Reappointments: Maria Johanna BORST, Isabel JOERIN and 3 others
Power of attorney24 points ▸
- General meeting, 05-06-2025
- Board meeting, 29-09-2025
- Other provision, “delegatie van bevoegdheden door raad van bestuur aan welbepaalde personen zoals voor datum van deze vergadering gepubliceerd in het Belgisch Staatsblad niet mee…” (deed in Dutch)
- Power of attorney, Fabrizio LONGHI, mentioned 2 times in the deed
- Power of attorney, Nizar SEBTI, mentioned 2 times in the deed
- Power of attorney, Luc VAN DRIESSCHE, mentioned 2 times in the deed
- Power of attorney, Thomas LIMBEROPOULOS, mentioned 2 times in the deed
- Power of attorney, Geert BUTSTRAEN, mentioned 2 times in the deed
- Power of attorney, Julie PIESSEVAUX, mentioned 2 times in the deed
- Power of attorney, Eva DE JONGH, mentioned 2 times in the deed
- Power of attorney, Maria Johanna BORST, mentioned 2 times in the deed
- Power of attorney, Stefaan FIERS, mentioned 2 times in the deed
- The act holds 12 more points.
17-06
financial year 2024 · full format
04-02
financial year 2023 · full format · 188 days late
31-01
Gazette deed
Resignations & appointmentsPower of attorney17 points ▸
Gazette deed
Resignations & appointments
Power of attorney17 points ▸
- Other provision, “dossiernummer”, 25016179 (deed in Dutch)
- Board meeting, 06-01-2025
- Other provision, “beëindiging eerdere delegatie, niet meer van toepassing” (deed in Dutch)
- Power of attorney, Fabrizio LONGHI, mentioned 2 times in the deed
- Power of attorney, Nizar SEBTI, mentioned 2 times in the deed
- Power of attorney, Luc VAN DRIESSCHE, mentioned 2 times in the deed
- Power of attorney, Thomas LIMBEROPOULOS, mentioned 2 times in the deed
- Power of attorney, Geert BUTSTRAEN, mentioned 2 times in the deed
- Power of attorney, Julie PIESSEVAUX, mentioned 2 times in the deed
- Power of attorney, Eva DE JONGH, mentioned 2 times in the deed
- Power of attorney, Maria Johanna BORST, mentioned 2 times in the deed
- Power of attorney, Roel PANNEELS
- The act holds 5 more points.
2024
18-07
Gazette deed
Permanent representatives: Ellemarie Bex and Tanguy Legein5 points ▸
Gazette deed
Permanent representatives: Ellemarie Bex and Tanguy Legein
5 points ▸
- General meeting, 06-06-2024
- Permanent representative, Ellemarie Bex
- Permanent representative, Tanguy Legein
- Other provision, “commissaris, commissaris” (deed in Dutch)
- Other provision, “1800 Vilvoorde,Medialaan 28B, advocatenkantoor” (deed in Dutch)
19-04
Gazette deed
Resignations & appointmentsPower of attorney17 points ▸
Gazette deed
Resignations & appointments
Power of attorney17 points ▸
- Board meeting, 27-03-2024
- Other provision, “intrekking delegatie van bevoegdheden, niet meer van toepassing” (deed in Dutch)
- Power of attorney, Marcos DEHOLLAIN, mentioned 2 times in the deed
- Power of attorney, Nizar SEBTI, mentioned 2 times in the deed
- Power of attorney, Luc VAN DRIESSCHE, mentioned 2 times in the deed
- Power of attorney, Thomas LIMBEROPOULOS, mentioned 2 times in the deed
- Power of attorney, Michèle MELHEM, mentioned 2 times in the deed
- Power of attorney, Geert BUTSTRAEN, mentioned 2 times in the deed
- Power of attorney, Julie PIESSEVAUX, mentioned 2 times in the deed
- Power of attorney, Eva DE JONGH, mentioned 2 times in the deed
- Power of attorney, Maria BORST, mentioned 2 times in the deed
- Power of attorney, Bart DECUYPERE
- The act holds 5 more points.
19-01
Gazette deed
Amendment of the articlesCapital · Power of attorney5 points ▸
Gazette deed
Amendment of the articles
Capital · Power of attorney5 points ▸
- General meeting, 14-12-2023
- Other provision, “taal van de Vennootschap, Nederlands” (deed in French)
- Amendment of the articles
- Capital, €32,000,000
- Power of attorney, mentioned 2 times in the deed
2023
31-12
Financial
Highest result from 2018 to 2025net €8.9m ▲3%
The net result of €8.9m is the highest of those years.
30-06
Gazette deed
Reappointment: KPMG BEDRIJFSREVISOREN REVISEURS D'ENTREPRISE BV/SRL (statutory auditor)Power of attorney18 points ▸
Gazette deed
Reappointment: KPMG BEDRIJFSREVISOREN REVISEURS D'ENTREPRISE BV/SRL (statutory auditor)
Power of attorney18 points ▸
- Board meeting, 28-03-2023
- Power of attorney, Marcos DEHOLLAIN, mentioned 2 times in the deed
- Power of attorney, Nizar SEBTI, mentioned 2 times in the deed
- Power of attorney, Luc VAN DRIESSCHE, mentioned 2 times in the deed
- Power of attorney, Thomas LIMBEROPOULOS, mentioned 2 times in the deed
- Power of attorney, Michèle MELHEM, mentioned 2 times in the deed
- Power of attorney, Geert BUTSTRAEN, mentioned 2 times in the deed
- Power of attorney, Julie PIESSEVAUX, mentioned 2 times in the deed
- Power of attorney, Eva DE JONGH, mentioned 2 times in the deed
- Power of attorney, Bart DECUYPERE, mentioned 2 times in the deed
- Power of attorney, Isabelle VAN DER HAEGEN
- Power of attorney, Roel PANNEELS, mentioned 2 times in the deed
- The act holds 6 more points.
Show earlier events
09-05
financial year 2022 · full format
04-01
Gazette deed
Resignations & appointmentsGeneral meeting1 point ▸
Gazette deed
Resignations & appointments
General meeting1 point ▸
- General meeting, 28-04-2022
2022
29-04
financial year 2021 · full format
2021
31-12
Financial
Equity above €50mequity €52.4m ▲19.4%
With a profit in every financial year since 2018, equity grows to €52.4m.
28-04
financial year 2020 · full format
2020
07-05
financial year 2019 · full format
2019
29-04
financial year 2018 · full format
2018
03-05
financial year 2017 · full format
2017
28-04
financial year 2016 · full format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
Register details
Identity
KBO recordName
ROCHE in Dutch
Enterprise number
0403.088.151
Legal form
Public limited company
Status
Active, normale toestand
Founded
12-02-1924
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 19-01-2024 (in French)Name clauseThe company operates under this name according to its articles.
Roche
deed of 19-01-2024 (in French)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Brussels Hoofdstedelijk Gewest”
deed of 19-01-2024 (in French)Registered office and establishments
Registered office
Dantestraat 75, 1070 Anderlecht, Belgium
Establishments
2 establishment units since 1924
Activities
NACEBEL 202521201
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
46460
Wholesale of pharmaceutical and medical goods main activity
20590
Manufacture of chemicals and chemical products
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 19-01-2024 (in French)
“Het op punt zetten,de fabricatie,de verwerking,de invoer,de uitvoer,de aankoop,de verkoop en de vertegenwoordiging van alle producten van de…”
6 activities
- Het op punt zetten,de fabricatie,de verwerking,de invoer,de uitvoer,de aankoop,de verkoop en de vertegenwoordiging van alle producten van de farmaceutische en biomedische nijverheden en van alle samenhangende nijverheden.
- De vennootschap zal alle merken,brevetten,en intellectuele eigendomsrechten mogen verwerven,verkrijgen,uitbaten en afstaan,die rechtstreeks of onrechtstreeks verband houden met haar voorwerp of die de verwezenlijking ervan kunnen vergemakkelijken.
- De vennootschap kan,in het algemeen,in België en in het buitenland,alle handelingen,transacties of commerciële,industriële,financiële roerende en onroerende activiteiten uitvoeren die rechtstreeks of onrechtstreeks,geheel of gedeeltelijk,verband houden met haar voorwerp of die de realisatie ervan kunnen vergemakkelijken of bevorderen.
- Zij kan belangen nemen door associatie,inbreng,fusie,financiële tussenkomst of op gelijk welke andere wijze,in alle vennootschappen,verenigingen of ondernemingen met een identiek,gelijklopend of samenhangend voorwerp met het hare,of die van aard kunnen zijn de ontwikkeling van haar onderneming te begunstigen of een bron van afzetten te vormen.
- Zij kan de functies van bestuurder of vereffenaar uitoefenen in andere vennootschappen.
- De vennootschap mag zich borg stellen of zakelijke zekerheden verlenen ten voordele van vennootschappen of particulieren,in de meest ruime zin.
Invoicing and payment
VAT number
BE 0403.088.151
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
First Thursday of June at 10:00
deed of 19-01-2024 (in French)The scores and ratios are Checked's own calculations, not a credit decision.
Recognitions · licences · registrations
Legal Entity Identifier
54930036NIIQZPO7LM03
Environmental permits: No permit applications found in Flanders.
Sites & property
Location
2 establishment units
Dantestraat 75, 1070 Anderlecht
since 1924unit number 2.003.056.631
Berkenlaan 8A, 1831 Machelen (Brab.)
since 2025unit number 2.378.693.287
Buildings and parcels at the addresses
Ground area
2.1 ha
Building footprint
2,747 m²
Building volume
48,418 m³
2 parcels, Brussels, Flanders · tallest building 26.6 m.
2 parcels
Flanders
1
(50%)
Brussels
1
(50%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 21306C0225/00C002 | Brussels | 1.2 ha | 1 · 1,356 m² | 19.1 m · 5 |
| 23015B0120/00E000 | Flanders | 9,322 m² | 1 · 1,390 m² | 26.6 m · 7 |